Denali Therapeutics (DNLI) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics today and set a price target of $37.00. The company’s shares closed yesterday at $14.98.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Ionis Pharmaceuticals, and Alnylam Pharma. According to TipRanks, Matteis has an average return of 15.4% and a 48.37% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Denali Therapeutics with a $33.00 average price target.

Based on Denali Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $124.12 million. In comparison, last year the company had a GAAP net loss of $99.03 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year. Most recently, in August 2025, Alexander O. Schuth, the COFO and Secretary of DNLI sold 2,937.00 shares for a total of $39,884.46.